Investing.com - Financial Markets Worldwide

Neurocrine Biosciences Inc (NBIX)

NASDAQ
Symbol
Exchange
Currency
NBIX·NASDAQ·USD
NBIX·TradeGate·EUR
Currency in USD
132.14
+0.50(+0.38%)
Closed·
After Hours
131.05-1.09(-0.82%)
·

NBIX Financial Summary

Key Ratios

P/E Ratio43.38
Price/Book5.22
Debt / Equity19.45%
Return on Equity12.43%
Dividend Yield0.00%
EBITDA610.10M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa1,045.91,133.51,488.71,887.12,355.3
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa760.8791.11,001.71,282.41,590.2
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa327.5207.8249394.8583
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa407.389.6154.5249.7341.3
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa1,734.72,072.52,368.73,251.43,718.7
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa186.5245.8537.7654.8507.7
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa1,126.21,3741,707.82,2322,589.7
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa278.59265.75247.63439.25457.98
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa228.5256.5339.4389.9595.4
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa4.1-130.2-177.1-467.1-126.8
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-157.827.4-234.365.3-486.7
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa74.8153.7-73.3-11.6-18.1
* In Millions of USD (except for per share items)

Analyst Ratings

23 Buy
3 Hold
0 Sell
Ratings:
26 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 163.76
(+23.93% Upside)

Earnings

Latest Release
May 05, 2025
EPS / Forecast
0.70 / 0.77
Revenue / Forecast
572.60M / 593.71M
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Neurocrine's earnings for the latest quarter?

The Neurocrine EPS (TTM) is 3.05. Neurocrine reported sales of 572.60, net income of 7.90, and EPS of 0.70 for the latest quarter.

What was Neurocrine's net income for the latest quarter?

Neurocrine's net income for the latest quarter was 7.90.

How did Neurocrine's performance compare year-over-year in the latest quarter?

The company's revenue moved from 627.70 in the previous quarter to 572.60 in the latest quarter, and net income moved from 103.10 to 7.90 compared to the previous quarter.

What is Neurocrine's net profit margin on a TTM basis?

Neurocrine's trailing twelve months (TTM) net profit margin is 14.49%.

How does Neurocrine's debt to equity ratio compare to industry standards?

Neurocrine's total debt-to-equity ratio is 19.45%.

What is Neurocrine's return on investment on a TTM basis?

Neurocrine's trailing twelve months (TTM) return on investment (ROI) is 12.43%.

Did Neurocrine gain or lose cash last quarter?

In the latest quarter, Neurocrine's net change in cash was -38.90 million.

What were Neurocrine's total assets and liabilities in the latest quarter?

As of the latest quarter, Neurocrine reported total assets of 3,687.70 million and total liabilities of 522.90 million.

How has Neurocrine's total revenue grown this year?

Neurocrine's total revenue was 627.70 in the previous quarter and 572.60 in the latest quarter.

What is Neurocrine's gross margin on a TTM basis?

Neurocrine's trailing twelve months (TTM) gross margin is 63.91%.

What was Neurocrine's revenue per share for the latest quarter?

Neurocrine's revenue per share for the latest quarter was 44.20.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.